10.3389/fonc.2019.00866.s001
Zhihua Si
Zhihua
Si
Shuisheng Zhang
Shuisheng
Zhang
Xiaowei Yang
Xiaowei
Yang
Nan Ding
Nan
Ding
Meiyi Xiang
Meiyi
Xiang
Qingshan Zhu
Qingshan
Zhu
Yantao Mao
Yantao
Mao
Yajuan Lv
Yajuan
Lv
Lili Yu
Lili
Yu
Heli Shang
Heli
Shang
Jian Xie
Jian
Xie
Yuan Tian
Yuan
Tian
Data_Sheet_1_The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.doc
Frontiers
2019
incidence risk
peripheral neuropathy
PD-1/PD-L1
solid tumor
meta-analysis
2019-09-04 04:08:13
Dataset
https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_The_Association_Between_the_Incidence_Risk_of_Peripheral_Neuropathy_and_PD-1_PD-L1_Inhibitors_in_the_Treatment_for_Solid_Tumor_Patients_A_Systematic_Review_and_Meta-Analysis_doc/9765431
<p>Purpose: We conducted this study to determine the relationship between PD-1/PD-L1 inhibitors and the incidence risk of peripheral neuropathy in patients with solid tumors.</p><p>Method: The process of the meta-analysis was performed by us according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Incidence of all-grade and grade 3–5 treatment-related peripheral neuropathy in patients with solid tumors were taken into account.</p><p>Results: After screening and eligibility assessment, a total of 17 clinical trials involving 10,500 patients were selected for the final meta-analysis. The incidence risk of peripheral neuropathy for all grade was significantly lower in the PD-1/PD-L1 inhibitor group than that of the control group, either monotherapy (OR = 0.08, 95%CI:[0.03, 0.19]) or chemotherapy (OR = 0.05, 95%CI:[0.03, 0.11]). Similar incidence trend could also be seen for the incidence risk of grade 3–5 peripheral neuropathy. When PD-1/PD-L1 inhibitors were used in combination with chemotherapy, the incidence risk of peripheral neuropathy was higher than in the control chemotherapy group, whether it was all-grade (OR = 1.22, 95%CI:[1.00, 1.49]) or grade 3–5 degree (OR = 1.74, 95%CI:[1.03, 2.92]).</p><p>Conclusion: Compared with chemotherapy, incidence risk of peripheral neuropathy related to PD-1/PD-L1 inhibitor was significantly lower than that of the chemotherapy group, while PD-1/PD-L1 inhibitor increased the incidence risk of peripheral neuropathy when it was combined with chemotherapy.</p>